{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:57:20Z","timestamp":1793141840898,"version":"4.5.0"},"reference-count":15,"publisher":"BMJ","issue":"5","funder":[{"name":"Eye Tumor Research Foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To develop a nomogram for prediction of visual acuity outcome following plaque radiotherapy for uveal melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective review of uveal melanoma treated with plaque radiotherapy and prophylactic intravitreal bevacizumab injections at 4-month intervals for 2 years duration. Two nomograms for poor visual acuity outcome (Snellen &lt;20\/200) were developed based on (1) Clinical risk factors. (2) Or clinical and treatment risk factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 1131 included cases. The most important clinical risk factors (points for nomogram) for poor visual acuity outcome included subretinal fluid involving four quadrants (100), tumour thickness &gt;4 mm (69), presenting visual acuity \u226420\/30 (65), non-Caucasian race (58), tumour shape mushroom, bilobed, or multilobulated (57), and insulin-dependent diabetes (54). Risk of poor visual acuity at 2 years and 4 years increased from 11% and 24% with 40 points to 97% and &gt;99% with 304 points. A second analysis was performed using both clinical and treatment risk factors. The most important factors included presenting visual acuity \u226420\/30 (100), tumour largest basal diameter &gt;11 mm (80), radiation dose rate to tumour base \u2265164 cGy\/hour (78), tumour thickness &gt;4 mm (76), insulin-dependent diabetes (75) and abnormal foveolar status by optical coherence tomography at presentation (72). Risk of poor visual acuity at 2 years and 4 years increased from 6% and 14% with 56 points to 88% and 99% with 496 points.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A nomogram using clinical or treatment risk factors can predict visual acuity outcome following plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma and is available online at <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/fighteyecancer.com\/nomograms\/\">https:\/\/fighteyecancer.com\/nomograms\/<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2019-314686","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T21:25:13Z","timestamp":1565731513000},"page":"697-702","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients"],"prefix":"10.1136","volume":"104","author":[{"given":"Lauren A","family":"Dalvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose A","family":"Hamershock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-3632","authenticated-orcid":false,"given":"Carol L","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2019-314686-1","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/archopht.118.9.1219","article-title":"Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients","volume":"118","author":"Shields","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2019-314686-2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0161-6420(00)00526-1","article-title":"Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. visual acuity after 3 years COMS report No. 16","volume":"108","author":"Melia","year":"2001","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2019-314686-3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","article-title":"Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma","volume":"121","author":"Shah","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2019-314686-4","first-page":"e285","article-title":"Plaque brachytherapy for uveal melanoma: a vision prognostication model. International Journal of radiation oncology, biology","volume":"84","author":"Khan","year":"2012","journal-title":"Physics"},{"key":"key-10.1136\/bjophthalmol-2019-314686-5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.5114\/jcb.2017.71795","article-title":"Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma","volume":"9","author":"Tagliaferri","year":"2017","journal-title":"J Contemp Brachytherapy"},{"key":"key-10.1136\/bjophthalmol-2019-314686-6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.brachy.2018.07.002","article-title":"Outcomes of choroidal melanomas treated with eye physics plaques: a 25-year review","volume":"17","author":"Le BHA","year":"2018","journal-title":"Brachytherapy"},{"key":"key-10.1136\/bjophthalmol-2019-314686-7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jamaophthalmol.2013.4422","article-title":"Outcomes of choroidal melanomas treated with eye physics","volume":"131","author":"Berry","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2019-314686-8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/950975","article-title":"Outcomes and control rates for I-125 plaque brachytherapy for uveal melanoma: a community-based institutional experience","volume":"2014","author":"Wagner","year":"2014","journal-title":"ISRN Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2019-314686-9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.brachy.2017.01.012","article-title":"Visual acuity, oncologic, and toxicity outcomes with 103 PD vs. 125 I plaque treatment for choroidal melanoma","volume":"16","author":"Patel","year":"2017","journal-title":"Brachytherapy"},{"key":"key-10.1136\/bjophthalmol-2019-314686-10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/jamaophthalmol.2014.111","article-title":"Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases","volume":"132","author":"Sagoo","year":"2014","journal-title":"JAMA ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2019-314686-11","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/00006982-200510000-00009","article-title":"Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma","volume":"25","author":"Shields","year":"2005","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2019-314686-12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5301\/ejo.5000352","article-title":"Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma","volume":"24","author":"Mashayekhi","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2019-314686-13","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/IAE.0b013e31816b3192","article-title":"Periocular triamcinolone for prevention of macular edema after iodine 125 plaque radiotherapy of uveal melanoma","volume":"28","author":"Horgan","year":"2008","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2019-314686-14","unstructured":"Shields CL\n, \nDalvin LA\n, \nChang M\n, et al\n. Prophylactic intravitreal bevacizumab (every 4 months for 2 years) after plaque radiotherapy for uveal melanoma: analysis of 1131 eyes of 1131 patients. In Press 2019."},{"key":"key-10.1136\/bjophthalmol-2019-314686-15","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in oncology: more than meets the eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2019-314686","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T09:01:22Z","timestamp":1601110882000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2019-314686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bjophthalmol-2019-314686"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314686","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]}}}